How it may work
A prescription GLP-1 receptor agonist used in indicated metabolic care.
Guide-level evidence orientationEvidence level B
Level B describes a substantial but bounded human evidence base for this exact question; read the conclusion for whether the result is positive, null or bounded.
This guide-level grade is an orientation, not a direction-of-effect label, product grade, claim or personal recommendation.Why people are interested
A GLP-1 medicine used in selected metabolic care. Its substantial human evidence relates to specific medical outcomes, not a universal longevity effect.
Library trackMedical research
Last reviewed20 Aug 2026
Guide scopeIngredient research only
What people have studied
Substantial human evidence supports selected obesity and diabetes indications; it is not a general anti-ageing drug.
What to consider
Prescription assessment, contraindication review, titration and clinical monitoring are essential.
Local pathway
Registered prescription products follow the medical pathway; never a CELLIVITY retail supplement.
Sources + indexes
See where the explanation comes from.
Open the linked research and official records behind this guide. Early topics may begin with a research index while stronger sources are added.